Feb222021 Anavex Life Sciences Announces Participation at Upcoming Worldwide National Institutes of Health (NIH) Panel at Rare Disease Day® February 22, 2021
Feb182021 Anavex Life Sciences to Present at the 10th Annual SVB Leerink Global Healthcare Conference on February 25, 2021 February 18, 2021
Dec222020 Anavex Life Sciences to Announce Fiscal 2020 Year End Financial Results December 28th, 2020 December 22, 2020
Nov302020 Anavex Life Sciences Announces Notice of Allowance for U.S. Patent Application with Expanding Claims Covering ANAVEX®2-73 (blarcamesine) for the Treatment of Rett Syndrome and other Neurodevelopmental Disorders November 30, 2020
Nov252020 Anavex Life Sciences to Present at the Evercore ISI 3rd Annual HealthCONx Conference November 25, 2020
Aug62020 Anavex Life Sciences Reports Fiscal 2020 Third Quarter Financial Results And Provides Business Updates August 6, 2020
Aug52020 Anavex Life Sciences Receives TGA Special Access Scheme Approval for ANAVEX®2-73 (blarcamesine) for Alzheimer’s Disease Patients August 5, 2020
Aug42020 Anavex Life Sciences to Announce Fiscal 2020 Third Quarter Financial Results on Thursday, August 6th, 2020 August 4, 2020
Dec102019 Anavex Life Sciences to Announce Fiscal 2019 Year End Financial Results on Monday December 16, 2019 December 10, 2019
Sep272019 Anavex Life Sciences Presented at the 6th Annual European Rett Syndrome Conference Preliminary Clinical Efficacy Data from the U.S. Rett Syndrome Phase 2 ANAVEX®2-73 Study September 27, 2019
Sep182019 Anavex Life Sciences to Present at the Ladenburg Thalmann 2019 Healthcare Conference September 18, 2019
